NCT06256484View on ClinicalTrials.gov

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 6, 2024

Primary Completion Date

March 3, 2025

Study Completion Date

March 30, 2025

Conditions
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Interventions
DRUG

ATA3219

ATA3219 is allogeneic anti-CD19 chimeric antigen receptor T-cell, administered intravenously on Day 1.

Trial Locations (6)

4102

Princess Alexandra Hospital, Woolloongabba

6150

Fiona Stanley Hospital, Murdoch

19107

Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia

22908

University of Virgina, Charlottesville

32804

AdventHealth Cancer Institute, Orlando

40207

Norton Cancer Institute - Saint Matthews, Louisville

Sponsors
All Listed Sponsors
lead

Atara Biotherapeutics

INDUSTRY

NCT06256484 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter